Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Bank of Montreal Can

Bank of Montreal Can decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 41.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,889 shares of the biotechnology company’s stock after selling 47,871 shares during the quarter. Bank of Montreal Can’s holdings in Exelixis were worth $1,549,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. LSV Asset Management increased its position in shares of Exelixis by 1,651.4% during the 1st quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock worth $65,844,000 after purchasing an additional 2,616,278 shares during the last quarter. Hsbc Holdings PLC increased its position in shares of Exelixis by 45.3% during the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock valued at $2,031,000 after acquiring an additional 28,126 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Exelixis by 948.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after acquiring an additional 2,220,150 shares during the period. True Wealth Design LLC acquired a new position in shares of Exelixis in the 4th quarter worth approximately $828,000. Finally, Intech Investment Management LLC boosted its position in shares of Exelixis by 155.8% during the 1st quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock worth $2,374,000 after purchasing an additional 60,925 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Trading Up 1.6 %

Shares of EXEL stock opened at $26.66 on Friday. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83. The company has a market cap of $8.08 billion, a P/E ratio of 41.66, a PEG ratio of 0.56 and a beta of 0.54. The firm has a fifty day moving average price of $25.85 and a 200 day moving average price of $23.57.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million. On average, equities analysts forecast that Exelixis, Inc. will post 1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Truist Financial reaffirmed a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Royal Bank of Canada increased their price target on shares of Exelixis from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a report on Friday, September 20th. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.87.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the transaction, the executive vice president now directly owns 520,990 shares in the company, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock worth $8,640,129 over the last three months. Insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.